7.3 Severe Infections in the ICU

Management of Severe ICU Infections

Patients in the Intensive Care Unit (ICU) are highly susceptible to healthcare-associated infections due to the presence of invasive devices (endotracheal tubes, central venous catheters, Foley catheters), altered immune function, and frequent exposure to broad-spectrum antibiotics. Effectively managing these infections is central to critical care pharmacy practice.

Ventilator-Associated Pneumonia (VAP)

VAP is defined as pneumonia developing >48 hours after endotracheal intubation. It is a major cause of morbidity and prolonged ICU length of stay.

Diagnosis

Diagnosis relies on clinical criteria (new or progressive radiographic infiltrate plus fever, leukocytosis/leukopenia, or purulent secretions) combined with microbiologic data. Non-invasive sampling (e.g., endotracheal aspiration) with semi-quantitative cultures is generally preferred over invasive sampling (e.g., bronchoalveolar lavage).

Empiric Antimicrobial Therapy

The 2016 IDSA/ATS guidelines emphasize tailoring empiric therapy based on local antibiograms and patient-specific risk factors for multi-drug resistant (MDR) pathogens.

• MRSA Coverage: Include an agent active against MRSA (vancomycin or linezolid) if the patient has a risk factor for antimicrobial resistance (e.g., prior IV antibiotics within 90 days, ARDS preceding VAP, 5+ days of hospitalization), is in a unit where >10% of S. aureus isolates are MRSA, or if local prevalence is unknown.
• Gram-Negative/Pseudomonal Coverage:
  • Single Coverage: One antipseudomonal agent (e.g., piperacillin-tazobactam, cefepime, meropenem) is sufficient if the patient has no risk factors for MDR pathogens and the ICU's resistance rate for the chosen agent is <10%.
  • Double Coverage: Two antipseudomonal agents from different classes (e.g., beta-lactam + aminoglycoside or fluoroquinolone) are required if the patient has risk factors for MDR pathogens or is in an ICU where >10% of Gram-negative isolates are resistant to the monotherapy agent.

Duration of Therapy

For both VAP and Hospital-Acquired Pneumonia (HAP), a 7-day course of antimicrobial therapy is recommended for most patients, rather than longer durations, provided they have a good clinical response.

Catheter-Related Bloodstream Infections (CRBSI)

CRBSIs, or Central Line-Associated Bloodstream Infections (CLABSIs), are significant complications of central venous catheters.

Management Strategy

1. Catheter Removal: The decision to remove the catheter depends on the pathogen and clinical status. The catheter must be removed if the patient is hemodynamically unstable, has severe sepsis/septic shock, or if the infection is caused by highly virulent organisms: Staphylococcus aureus, Pseudomonas aeruginosa, Candida species, or enterococci. In these cases, attempting to salvage the line is associated with high failure rates and metastatic infections (e.g., endocarditis).
2. Empiric Therapy: Initiate broad-spectrum therapy covering both Gram-positive (vancomycin) and Gram-negative pathogens (e.g., cefepime or piperacillin-tazobactam). The Gram-negative coverage is particularly important if the patient is critically ill, neutropenic, or has a femoral catheter.
3. Duration: If the catheter is removed, uncomplicated S. aureus bacteremia requires at least 14 days of therapy (some experts recommend up to 4-6 weeks to prevent endocarditis). Coagulase-negative staphylococci often require 5-7 days after removal. Uncomplicated Gram-negative bacteremia is typically treated for 7-14 days.

Complicated Intra-Abdominal Infections (cIAI)

Complicated intra-abdominal infections extend beyond the hollow viscus of origin into the peritoneal space (e.g., perforated appendicitis, diverticulitis with abscess, bowel perforation).

Source Control

Source control is the most critical intervention in cIAI. Without adequate surgical debridement or percutaneous drainage, antimicrobial therapy alone will fail.

Pharmacotherapy

Empiric regimens must cover enteric Gram-negative bacilli and anaerobes (e.g., Bacteroides fragilis).

• Community-Acquired (Mild/Moderate): Cefazolin or ceftriaxone + metronidazole, OR ertapenem.
• Healthcare-Associated or High-Risk: Piperacillin-tazobactam, or cefepime + metronidazole, or a broad-spectrum carbapenem (meropenem, imipenem). Coverage for MRSA or Enterococcus may be added in high-risk patients with prior failures or specific colonizations.

Duration of Therapy

The STOP-IT trial revolutionized cIAI management. It demonstrated that in patients with adequate source control, a short course of antibiotics (4 days) is just as effective as a longer course (until resolution of systemic signs of infection). If source control is not achievable, longer durations are required.

Clostridioides difficile Infection (CDI) in the ICU

CDI is a major concern in the ICU due to the high volume of broad-spectrum antibiotic use. ICU patients frequently present with severe or fulminant CDI.

Definitions and Treatment

• Severe CDI: Defined by a WBC count > 15,000 cells/mL or a serum creatinine > 1.5 mg/dL.
  • Treatment: Oral fidaxomicin 200 mg BID for 10 days or oral vancomycin 125 mg QID for 10 days.
• Fulminant CDI: Characterized by hypotension, shock, ileus, or toxic megacolon.
  • Treatment: This requires aggressive therapy. The regimen of choice is high-dose oral vancomycin (500 mg QID), either by mouth or via a nasogastric tube, combined with intravenous metronidazole (500 mg Q8H). If an ileus is present, vancomycin enemas can also be added. Early surgical consultation for potential colectomy is vital.